David Roblin
Chief Executive Officer
Home
Transformative medicines, through transformational understanding of disease
Relation is building a generational pharmaceutical company with AI at its core.
Founded on a biology-first approach, the company has developed proprietary AI and experimental platforms that drive deep mechanistic understanding of disease across the full drug development cycle, advancing programmes in bone, cardiorenal, dermatology and rheumatology.
Focus on diseases where we transform confidence in biology
• Using AI, genetics and massive proprietary datasets.
Determine what biology to prosecute for a given disease
• Using the Relation Discovery Platform.
Discover or acquire molecules, working with leading partners
• Remain modality agnostic, let the biology speak.
Deploy AI and data to improve clinical probability of success
• Using the Relation Development Platform.
Develop molecules to clinical value inflection points
• Asset centric development with deep translational thought.
Our science
Medicines born from high-resolution biology, machine learning and clinical insights.
Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.
Our team
Interdisciplinary collaboration.
Immense impact.
Relation is led by experienced drug developers, computational scientists and entrepreneurs with experience across biotech, pharma, venture and academic research. We have a hunger to transform drug development as we know it — because the patient is waiting.
Join our team.
We are seeking world-class talent across biology, machine learning and drug discovery. Explore our opportunities here.
Read our news
Read more-
GSK pens $110M biological datasets pact with AI biotech Relation
Fierce Biotech
In the news 30 Jul 2026
-
Relation Announces Expanded Collaboration with GSK
Global newswire
Press release 30 Jul 2026
-
Relation unveils MORGAN, the next-generation model of cellular biology
Global Newswire
Press release 30 Jul 2026
-
Relation promises 'transformationally different success rates' in expanded AI pact with GSK
Endpoints news
In the news 30 Jul 2026
Leadership
-
-
Lindsay Edwards
Chief Technology Officer
-
Rosie Rodriguez
President, Growth
-
Benjamin Swerner
Chief Operating Officer
-
Jake Taylor-King
Chief Innovation Officer
-
Dave Powell
President of Drug Discovery
-
Matthew Page
VP, Data Science
Scientific Advisory Board
-
Michael Bronstein
DeepMind Professor of AI, University of Oxford
-
Caroline Uhler
Professor, MIT and Co-director of The Eric & Wendy Schmidt Center, The Broad Institute
-
Alex Shalek
J. W. Kieckhefer Professor, Department of Chemistry, MIT
-
Jacob Corn
Professor of Genome Biology, ETH Zurich and Co-founder, Spotlight Therapeutics
-
John Whittaker
Director, MRC Biostatistics Unit and Professor of Biostatistics, University of Cambridge
-
Marc Wein
Associate Professor of Medicine, Mass. Gen. Hospital and Harvard Medical School
Board and observers
-
Christine Aylward
Managing Partner, Magnetic Ventures
-
David Roblin
Chief Executive Officer, Relation
-
Charles Roberts
Chair, Relation
-
Jason Pontin
General Partner, DCVC
-
Zachary Bogue
Managing Partner, DCVC
-
Alex Morgan
Partner, Khosla Ventures
-
Jim Mellon
Deputy-chair, Juvenescece
-
Jake Taylor-King
Chief Innovation Officer, Relation
-
Benjamin Swerner
Chief Operating Officer, Relation
-
John Wesley
Investment Director at NVentures
-
Joanna Soroka
Principal at Hitachi Ventures
Key investors
-
Magnetic Ventures
-
DCVC
-
Khosla Ventures
-
Firstminute Capital
-
NVIDIA - Investor
-
GSK
-
Novartis
-
Hitachi Investments
-
Ark Invest
-
Deerfield
